EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015

David S Lopez, Omer Abdelgadir, Yuanyi Zhang, Jesús Gibran Hernández-Pérez iD, Maryam R Hussain iD, Mohanad Albayyaa iD, Rasmi Nair, Yong-Fang Kuo, Jaime P Almandoz iD, Lindsay G Cowell, Sarah E Messiah

Obesity · 2026-06 · 34 (6) · 1343-1353

DOI: 10.1002/oby.70211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 04.05.2026. Verfasst von David S Lopez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Peter O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Obesity, Neoplasms, Anti-Obesity Agents. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.

Methods

We conducted a retrospective cohort study using SEER–Medicare data from 2007 to 2015. The study included 46,552 women aged ≥ 65 years: ORCa survivors ( n = 23,276) and age‐ and index‐matched cancer‐free women ( n = 23,276). Prediagnostic AOM prescriptions before CVD onset were examined using intent‐to‐treat (ITT) and per‐protocol approaches. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% CI for incident CVD.

Results

In ITT analyses, AOM use was associated with lower CVD incidence in the composite analytic sample (HR = 0.80, 95% CI: 0.71–0.90) and among cancer‐free women (HR = 0.70, 95% CI: 0.58–0.85). Among ORCa survivors, estimates suggested a similar direction but were not statistically significant. In per‐protocol analyses, AOM use was associated with reduced CVD risk in ORCa survivors (HR = 0.74, 95% CI: 0.57–0.94) and cancer‐free women (HR = 0.59, 95% CI: 0.45–0.77). These associations were more pronounced within the first 2 years of follow‐up.

Conclusions

AOM use was inversely associated with incident CVD among ORCa survivors and cancer‐free women. Further studies of second‐generation AOM, particularly glucagon‐like peptide‐1 receptor agonists, are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesObesityNeoplasmsAnti-Obesity AgentsHumansFemaleUnited StatesAgedSEER ProgramRetrospective StudiesMedicareAged, 80 and overIncidenceProportional Hazards Models

Stichwörter der Autor:innen

breastcancercardiovascular diseasecolorectalendometrialovariansurvivorsweight loss medication

Substanzen

Anti-Obesity Agents

Autor:innen und Institutionen

  • Peter O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
  • Center for Population Health Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
  • Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
  • Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.

ORCID-Profile: Jesús Gibran Hernández-Pérez, Maryam R Hussain, Mohanad Albayyaa, Jaime P Almandoz

Förderung

  • NCI NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • National Cancer Institute

Zitieren

APA

Lopez, D. S., Abdelgadir, O., Zhang, Y., Hernández-Pérez, J. G., Hussain, M. R., Albayyaa, M., Nair, R., Kuo, Y. F., Almandoz, J. P., Cowell, L. G., & Messiah, S. E. (2026). Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015. Obesity, 34(6), 1343-1353. https://doi.org/10.1002/oby.70211

Vancouver

Lopez DS, Abdelgadir O, Zhang Y, Hernández-Pérez JG, Hussain MR, Albayyaa M, et al. Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015. Obesity. 2026;34(6):1343-1353. doi:10.1002/oby.70211

BibTeX
@article{Lopez2026,
  author = {Lopez, David S and Abdelgadir, Omer and Zhang, Yuanyi and Hernández-Pérez, Jesús Gibran and Hussain, Maryam R and Albayyaa, Mohanad and Nair, Rasmi and Kuo, Yong-Fang and Almandoz, Jaime P and Cowell, Lindsay G and Messiah, Sarah E},
  title = {Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {6},
  pages = {1343--1353},
  doi = {10.1002/oby.70211}
}
Kostenlos starten →